Poor pretransplantation minimal residual disease clearance as an independent prognostic risk factor for survival in myelodysplastic syndrome with excess blasts: A multicenter, retrospective cohort study
Background Minimal residual disease (MRD) is an important prognostic factor for survival in adults with acute leukemia. The role of pretransplantation MRD status in myelodysplastic syndrome with excess blasts (MDS‐EB) is unknown. This study retrospectively analyzed the relationship between pretransp...
Gespeichert in:
| Veröffentlicht in: | Cancer 2023-07, Vol.129 (13), p.2013-2022 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2022 |
|---|---|
| container_issue | 13 |
| container_start_page | 2013 |
| container_title | Cancer |
| container_volume | 129 |
| creator | Ma, Ying‐Ying Wei, Ze‐liang Xu, Ya‐Jing Shi, Ji‐Min Yi, Hai Lai, Yong‐Rong Jiang, Er‐Lie Wang, San‐Bin Wu, Tao Gao, Lei Gao, Li Kong, Pei‐Yan Wen, Qin Bai, Hai Li, Yu Cao, Yi‐geng Li, Qiao‐Chuan Zhang, Zhong‐Ming Liu, Bei‐Cai Su, Yi Lai, Xiao‐Yu Ma, Xia Cheng, Ting‐Ting Luo, Yi Zhang, Xi Zhang, Cheng |
| description | Background
Minimal residual disease (MRD) is an important prognostic factor for survival in adults with acute leukemia. The role of pretransplantation MRD status in myelodysplastic syndrome with excess blasts (MDS‐EB) is unknown. This study retrospectively analyzed the relationship between pretransplantation MRD status and long‐term survival.
Materials and Methods
Patients with MDS‐EB who underwent allogeneic hematopoietic stem cell transplantation (allo‐HSCT) from March 5, 2005, to November 8, 2020, were included. The relationship between pretransplantation MRD status and long‐term survival was analyzed using univariate and multivariate logistic regression models.
Results
Of 220 patients with MDS‐EB who underwent allo‐HSCT, 198 were eligible for inclusion in this multicenter, retrospective cohort study. Complete remission was attained in 121 (61.1%) patients, and 103 patients underwent detection of MRD pretransplantation, with 67 patients being MRD‐positive and 36 patients being MRD‐negative. The median follow‐up time was 16 months, the median age was 41 years (6–65 years), and 58% of the patients were men. The 3‐year disease‐free survival (DFS) and overall survival (OS) probabilities for all patients were 70.1% and 72.9%, respectively. For patients in complete remission, the 3‐year DFS and OS probabilities were 72.2% and 74.8%, respectively. Further analysis found that the 3‐year DFS rates of MRD‐negative and MRD‐positive patients were 85.6% and 66.5% (p = .045), respectively, whereas the 3‐year OS rates were 91.3% and 66.4% (p = .035), respectively. Univariate and multivariate analyses showed that poor pretransplantation MRD clearance was an independent prognostic risk factor for DFS and OS.
Conclusion
Poor pretransplantation MRD clearance is an independent prognostic risk factor for long‐term survival after allo‐HSCT for patients with MDS‐EB.
Plain language summary
Poor minimal residual disease clearance pretransplanation is an independent prognostic risk factor for long‐term survival after allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome with excess blasts.
The role of minimal residual disease (MRD) status pretransplantation in the survival of patients with myelodysplastic syndrome with excess blasts after allogeneic hematopoietic stem cell transplantation in present multicenter, retrospective, cohort study was evaluated. The primary outcome showed that MRD status was the only independent prognostic factor |
| doi_str_mv | 10.1002/cncr.34762 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2790050835</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2824329892</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3572-2feab0056e7ebda0d5806d35028c2dbe677222cac447d5d80afa3ca5a579aa103</originalsourceid><addsrcrecordid>eNp9kc9u1DAQhyMEotvChQdAlrggRIrjxHHCrVpRQKoAIZC4RY49oS6JvfU4W_KKPBWTbuHAgYP_yZ8-z_iXZU8KflpwLl4Zb-JpWala3Ms2BW9VzotK3M82nPMml1X57Sg7RryioxKyfJgdlXUri6ptNtmvTyFEtouQova4G7VPOrng2eS8m_TIIqCzM22sQ9AIzIygiTXANDLtmfMWdkCTT-QJ333A5AyLDn-wQZtE-oEGznHv9uRx5F5gDHZZn7tlcfE2hgnYjUuXDH4aQGT9eomv2Rmb5pEo8kN8ydZKA-7AJLenYsJliIlhmu3yKHsw6BHh8d16kn09f_Nl-y6_-Pj2_fbsIjelVCIXA-iec1mDgt5qbmXDa1tKLhojbA-1UkIIo01VKSttw_WgS6OllqrVuuDlSfb84KVur2fA1E0ODYz0dxBm7IRqSc-bUhL67B_0KszRU3WdaERVirZpBVEvDpShzjDC0O0i_X1cuoJ3a8LdmnB3mzDBT--Ucz-B_Yv-iZSA4gDcuBGW_6i67Yft54P0N5C3uAQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2824329892</pqid></control><display><type>article</type><title>Poor pretransplantation minimal residual disease clearance as an independent prognostic risk factor for survival in myelodysplastic syndrome with excess blasts: A multicenter, retrospective cohort study</title><source>Wiley Free Content</source><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Ma, Ying‐Ying ; Wei, Ze‐liang ; Xu, Ya‐Jing ; Shi, Ji‐Min ; Yi, Hai ; Lai, Yong‐Rong ; Jiang, Er‐Lie ; Wang, San‐Bin ; Wu, Tao ; Gao, Lei ; Gao, Li ; Kong, Pei‐Yan ; Wen, Qin ; Bai, Hai ; Li, Yu ; Cao, Yi‐geng ; Li, Qiao‐Chuan ; Zhang, Zhong‐Ming ; Liu, Bei‐Cai ; Su, Yi ; Lai, Xiao‐Yu ; Ma, Xia ; Cheng, Ting‐Ting ; Luo, Yi ; Zhang, Xi ; Zhang, Cheng</creator><creatorcontrib>Ma, Ying‐Ying ; Wei, Ze‐liang ; Xu, Ya‐Jing ; Shi, Ji‐Min ; Yi, Hai ; Lai, Yong‐Rong ; Jiang, Er‐Lie ; Wang, San‐Bin ; Wu, Tao ; Gao, Lei ; Gao, Li ; Kong, Pei‐Yan ; Wen, Qin ; Bai, Hai ; Li, Yu ; Cao, Yi‐geng ; Li, Qiao‐Chuan ; Zhang, Zhong‐Ming ; Liu, Bei‐Cai ; Su, Yi ; Lai, Xiao‐Yu ; Ma, Xia ; Cheng, Ting‐Ting ; Luo, Yi ; Zhang, Xi ; Zhang, Cheng</creatorcontrib><description>Background
Minimal residual disease (MRD) is an important prognostic factor for survival in adults with acute leukemia. The role of pretransplantation MRD status in myelodysplastic syndrome with excess blasts (MDS‐EB) is unknown. This study retrospectively analyzed the relationship between pretransplantation MRD status and long‐term survival.
Materials and Methods
Patients with MDS‐EB who underwent allogeneic hematopoietic stem cell transplantation (allo‐HSCT) from March 5, 2005, to November 8, 2020, were included. The relationship between pretransplantation MRD status and long‐term survival was analyzed using univariate and multivariate logistic regression models.
Results
Of 220 patients with MDS‐EB who underwent allo‐HSCT, 198 were eligible for inclusion in this multicenter, retrospective cohort study. Complete remission was attained in 121 (61.1%) patients, and 103 patients underwent detection of MRD pretransplantation, with 67 patients being MRD‐positive and 36 patients being MRD‐negative. The median follow‐up time was 16 months, the median age was 41 years (6–65 years), and 58% of the patients were men. The 3‐year disease‐free survival (DFS) and overall survival (OS) probabilities for all patients were 70.1% and 72.9%, respectively. For patients in complete remission, the 3‐year DFS and OS probabilities were 72.2% and 74.8%, respectively. Further analysis found that the 3‐year DFS rates of MRD‐negative and MRD‐positive patients were 85.6% and 66.5% (p = .045), respectively, whereas the 3‐year OS rates were 91.3% and 66.4% (p = .035), respectively. Univariate and multivariate analyses showed that poor pretransplantation MRD clearance was an independent prognostic risk factor for DFS and OS.
Conclusion
Poor pretransplantation MRD clearance is an independent prognostic risk factor for long‐term survival after allo‐HSCT for patients with MDS‐EB.
Plain language summary
Poor minimal residual disease clearance pretransplanation is an independent prognostic risk factor for long‐term survival after allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome with excess blasts.
The role of minimal residual disease (MRD) status pretransplantation in the survival of patients with myelodysplastic syndrome with excess blasts after allogeneic hematopoietic stem cell transplantation in present multicenter, retrospective, cohort study was evaluated. The primary outcome showed that MRD status was the only independent prognostic factor that affects long‐term survival.</description><identifier>ISSN: 0008-543X</identifier><identifier>EISSN: 1097-0142</identifier><identifier>DOI: 10.1002/cncr.34762</identifier><identifier>PMID: 36951498</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Adult ; Allografts ; Cohort analysis ; disease‐free survival ; Female ; Hematopoietic Stem Cell Transplantation ; Hematopoietic stem cells ; Humans ; independent prognostic risk ; Leukemia ; Leukemia, Myeloid, Acute ; Male ; Medical prognosis ; Minimal residual disease ; Multivariate analysis ; Myelodysplastic syndrome ; myelodysplastic syndrome with excess blasts ; Myelodysplastic syndromes ; Myelodysplastic Syndromes - therapy ; Neoplasm, Residual - diagnosis ; Oncology ; overall survival ; Prognosis ; Regression analysis ; Regression models ; Remission ; Remission (Medicine) ; Retrospective Studies ; Risk Factors ; Stem cell transplantation ; Stem cells ; Survival ; Transplantation</subject><ispartof>Cancer, 2023-07, Vol.129 (13), p.2013-2022</ispartof><rights>2023 American Cancer Society.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3572-2feab0056e7ebda0d5806d35028c2dbe677222cac447d5d80afa3ca5a579aa103</citedby><cites>FETCH-LOGICAL-c3572-2feab0056e7ebda0d5806d35028c2dbe677222cac447d5d80afa3ca5a579aa103</cites><orcidid>0000-0003-0142-3307</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fcncr.34762$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fcncr.34762$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,1427,27901,27902,45550,45551,46384,46808</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36951498$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ma, Ying‐Ying</creatorcontrib><creatorcontrib>Wei, Ze‐liang</creatorcontrib><creatorcontrib>Xu, Ya‐Jing</creatorcontrib><creatorcontrib>Shi, Ji‐Min</creatorcontrib><creatorcontrib>Yi, Hai</creatorcontrib><creatorcontrib>Lai, Yong‐Rong</creatorcontrib><creatorcontrib>Jiang, Er‐Lie</creatorcontrib><creatorcontrib>Wang, San‐Bin</creatorcontrib><creatorcontrib>Wu, Tao</creatorcontrib><creatorcontrib>Gao, Lei</creatorcontrib><creatorcontrib>Gao, Li</creatorcontrib><creatorcontrib>Kong, Pei‐Yan</creatorcontrib><creatorcontrib>Wen, Qin</creatorcontrib><creatorcontrib>Bai, Hai</creatorcontrib><creatorcontrib>Li, Yu</creatorcontrib><creatorcontrib>Cao, Yi‐geng</creatorcontrib><creatorcontrib>Li, Qiao‐Chuan</creatorcontrib><creatorcontrib>Zhang, Zhong‐Ming</creatorcontrib><creatorcontrib>Liu, Bei‐Cai</creatorcontrib><creatorcontrib>Su, Yi</creatorcontrib><creatorcontrib>Lai, Xiao‐Yu</creatorcontrib><creatorcontrib>Ma, Xia</creatorcontrib><creatorcontrib>Cheng, Ting‐Ting</creatorcontrib><creatorcontrib>Luo, Yi</creatorcontrib><creatorcontrib>Zhang, Xi</creatorcontrib><creatorcontrib>Zhang, Cheng</creatorcontrib><title>Poor pretransplantation minimal residual disease clearance as an independent prognostic risk factor for survival in myelodysplastic syndrome with excess blasts: A multicenter, retrospective cohort study</title><title>Cancer</title><addtitle>Cancer</addtitle><description>Background
Minimal residual disease (MRD) is an important prognostic factor for survival in adults with acute leukemia. The role of pretransplantation MRD status in myelodysplastic syndrome with excess blasts (MDS‐EB) is unknown. This study retrospectively analyzed the relationship between pretransplantation MRD status and long‐term survival.
Materials and Methods
Patients with MDS‐EB who underwent allogeneic hematopoietic stem cell transplantation (allo‐HSCT) from March 5, 2005, to November 8, 2020, were included. The relationship between pretransplantation MRD status and long‐term survival was analyzed using univariate and multivariate logistic regression models.
Results
Of 220 patients with MDS‐EB who underwent allo‐HSCT, 198 were eligible for inclusion in this multicenter, retrospective cohort study. Complete remission was attained in 121 (61.1%) patients, and 103 patients underwent detection of MRD pretransplantation, with 67 patients being MRD‐positive and 36 patients being MRD‐negative. The median follow‐up time was 16 months, the median age was 41 years (6–65 years), and 58% of the patients were men. The 3‐year disease‐free survival (DFS) and overall survival (OS) probabilities for all patients were 70.1% and 72.9%, respectively. For patients in complete remission, the 3‐year DFS and OS probabilities were 72.2% and 74.8%, respectively. Further analysis found that the 3‐year DFS rates of MRD‐negative and MRD‐positive patients were 85.6% and 66.5% (p = .045), respectively, whereas the 3‐year OS rates were 91.3% and 66.4% (p = .035), respectively. Univariate and multivariate analyses showed that poor pretransplantation MRD clearance was an independent prognostic risk factor for DFS and OS.
Conclusion
Poor pretransplantation MRD clearance is an independent prognostic risk factor for long‐term survival after allo‐HSCT for patients with MDS‐EB.
Plain language summary
Poor minimal residual disease clearance pretransplanation is an independent prognostic risk factor for long‐term survival after allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome with excess blasts.
The role of minimal residual disease (MRD) status pretransplantation in the survival of patients with myelodysplastic syndrome with excess blasts after allogeneic hematopoietic stem cell transplantation in present multicenter, retrospective, cohort study was evaluated. The primary outcome showed that MRD status was the only independent prognostic factor that affects long‐term survival.</description><subject>Adult</subject><subject>Allografts</subject><subject>Cohort analysis</subject><subject>disease‐free survival</subject><subject>Female</subject><subject>Hematopoietic Stem Cell Transplantation</subject><subject>Hematopoietic stem cells</subject><subject>Humans</subject><subject>independent prognostic risk</subject><subject>Leukemia</subject><subject>Leukemia, Myeloid, Acute</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Minimal residual disease</subject><subject>Multivariate analysis</subject><subject>Myelodysplastic syndrome</subject><subject>myelodysplastic syndrome with excess blasts</subject><subject>Myelodysplastic syndromes</subject><subject>Myelodysplastic Syndromes - therapy</subject><subject>Neoplasm, Residual - diagnosis</subject><subject>Oncology</subject><subject>overall survival</subject><subject>Prognosis</subject><subject>Regression analysis</subject><subject>Regression models</subject><subject>Remission</subject><subject>Remission (Medicine)</subject><subject>Retrospective Studies</subject><subject>Risk Factors</subject><subject>Stem cell transplantation</subject><subject>Stem cells</subject><subject>Survival</subject><subject>Transplantation</subject><issn>0008-543X</issn><issn>1097-0142</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc9u1DAQhyMEotvChQdAlrggRIrjxHHCrVpRQKoAIZC4RY49oS6JvfU4W_KKPBWTbuHAgYP_yZ8-z_iXZU8KflpwLl4Zb-JpWala3Ms2BW9VzotK3M82nPMml1X57Sg7RryioxKyfJgdlXUri6ptNtmvTyFEtouQova4G7VPOrng2eS8m_TIIqCzM22sQ9AIzIygiTXANDLtmfMWdkCTT-QJ333A5AyLDn-wQZtE-oEGznHv9uRx5F5gDHZZn7tlcfE2hgnYjUuXDH4aQGT9eomv2Rmb5pEo8kN8ydZKA-7AJLenYsJliIlhmu3yKHsw6BHh8d16kn09f_Nl-y6_-Pj2_fbsIjelVCIXA-iec1mDgt5qbmXDa1tKLhojbA-1UkIIo01VKSttw_WgS6OllqrVuuDlSfb84KVur2fA1E0ODYz0dxBm7IRqSc-bUhL67B_0KszRU3WdaERVirZpBVEvDpShzjDC0O0i_X1cuoJ3a8LdmnB3mzDBT--Ucz-B_Yv-iZSA4gDcuBGW_6i67Yft54P0N5C3uAQ</recordid><startdate>20230701</startdate><enddate>20230701</enddate><creator>Ma, Ying‐Ying</creator><creator>Wei, Ze‐liang</creator><creator>Xu, Ya‐Jing</creator><creator>Shi, Ji‐Min</creator><creator>Yi, Hai</creator><creator>Lai, Yong‐Rong</creator><creator>Jiang, Er‐Lie</creator><creator>Wang, San‐Bin</creator><creator>Wu, Tao</creator><creator>Gao, Lei</creator><creator>Gao, Li</creator><creator>Kong, Pei‐Yan</creator><creator>Wen, Qin</creator><creator>Bai, Hai</creator><creator>Li, Yu</creator><creator>Cao, Yi‐geng</creator><creator>Li, Qiao‐Chuan</creator><creator>Zhang, Zhong‐Ming</creator><creator>Liu, Bei‐Cai</creator><creator>Su, Yi</creator><creator>Lai, Xiao‐Yu</creator><creator>Ma, Xia</creator><creator>Cheng, Ting‐Ting</creator><creator>Luo, Yi</creator><creator>Zhang, Xi</creator><creator>Zhang, Cheng</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>7U7</scope><scope>C1K</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-0142-3307</orcidid></search><sort><creationdate>20230701</creationdate><title>Poor pretransplantation minimal residual disease clearance as an independent prognostic risk factor for survival in myelodysplastic syndrome with excess blasts: A multicenter, retrospective cohort study</title><author>Ma, Ying‐Ying ; Wei, Ze‐liang ; Xu, Ya‐Jing ; Shi, Ji‐Min ; Yi, Hai ; Lai, Yong‐Rong ; Jiang, Er‐Lie ; Wang, San‐Bin ; Wu, Tao ; Gao, Lei ; Gao, Li ; Kong, Pei‐Yan ; Wen, Qin ; Bai, Hai ; Li, Yu ; Cao, Yi‐geng ; Li, Qiao‐Chuan ; Zhang, Zhong‐Ming ; Liu, Bei‐Cai ; Su, Yi ; Lai, Xiao‐Yu ; Ma, Xia ; Cheng, Ting‐Ting ; Luo, Yi ; Zhang, Xi ; Zhang, Cheng</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3572-2feab0056e7ebda0d5806d35028c2dbe677222cac447d5d80afa3ca5a579aa103</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Adult</topic><topic>Allografts</topic><topic>Cohort analysis</topic><topic>disease‐free survival</topic><topic>Female</topic><topic>Hematopoietic Stem Cell Transplantation</topic><topic>Hematopoietic stem cells</topic><topic>Humans</topic><topic>independent prognostic risk</topic><topic>Leukemia</topic><topic>Leukemia, Myeloid, Acute</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Minimal residual disease</topic><topic>Multivariate analysis</topic><topic>Myelodysplastic syndrome</topic><topic>myelodysplastic syndrome with excess blasts</topic><topic>Myelodysplastic syndromes</topic><topic>Myelodysplastic Syndromes - therapy</topic><topic>Neoplasm, Residual - diagnosis</topic><topic>Oncology</topic><topic>overall survival</topic><topic>Prognosis</topic><topic>Regression analysis</topic><topic>Regression models</topic><topic>Remission</topic><topic>Remission (Medicine)</topic><topic>Retrospective Studies</topic><topic>Risk Factors</topic><topic>Stem cell transplantation</topic><topic>Stem cells</topic><topic>Survival</topic><topic>Transplantation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ma, Ying‐Ying</creatorcontrib><creatorcontrib>Wei, Ze‐liang</creatorcontrib><creatorcontrib>Xu, Ya‐Jing</creatorcontrib><creatorcontrib>Shi, Ji‐Min</creatorcontrib><creatorcontrib>Yi, Hai</creatorcontrib><creatorcontrib>Lai, Yong‐Rong</creatorcontrib><creatorcontrib>Jiang, Er‐Lie</creatorcontrib><creatorcontrib>Wang, San‐Bin</creatorcontrib><creatorcontrib>Wu, Tao</creatorcontrib><creatorcontrib>Gao, Lei</creatorcontrib><creatorcontrib>Gao, Li</creatorcontrib><creatorcontrib>Kong, Pei‐Yan</creatorcontrib><creatorcontrib>Wen, Qin</creatorcontrib><creatorcontrib>Bai, Hai</creatorcontrib><creatorcontrib>Li, Yu</creatorcontrib><creatorcontrib>Cao, Yi‐geng</creatorcontrib><creatorcontrib>Li, Qiao‐Chuan</creatorcontrib><creatorcontrib>Zhang, Zhong‐Ming</creatorcontrib><creatorcontrib>Liu, Bei‐Cai</creatorcontrib><creatorcontrib>Su, Yi</creatorcontrib><creatorcontrib>Lai, Xiao‐Yu</creatorcontrib><creatorcontrib>Ma, Xia</creatorcontrib><creatorcontrib>Cheng, Ting‐Ting</creatorcontrib><creatorcontrib>Luo, Yi</creatorcontrib><creatorcontrib>Zhang, Xi</creatorcontrib><creatorcontrib>Zhang, Cheng</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ma, Ying‐Ying</au><au>Wei, Ze‐liang</au><au>Xu, Ya‐Jing</au><au>Shi, Ji‐Min</au><au>Yi, Hai</au><au>Lai, Yong‐Rong</au><au>Jiang, Er‐Lie</au><au>Wang, San‐Bin</au><au>Wu, Tao</au><au>Gao, Lei</au><au>Gao, Li</au><au>Kong, Pei‐Yan</au><au>Wen, Qin</au><au>Bai, Hai</au><au>Li, Yu</au><au>Cao, Yi‐geng</au><au>Li, Qiao‐Chuan</au><au>Zhang, Zhong‐Ming</au><au>Liu, Bei‐Cai</au><au>Su, Yi</au><au>Lai, Xiao‐Yu</au><au>Ma, Xia</au><au>Cheng, Ting‐Ting</au><au>Luo, Yi</au><au>Zhang, Xi</au><au>Zhang, Cheng</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Poor pretransplantation minimal residual disease clearance as an independent prognostic risk factor for survival in myelodysplastic syndrome with excess blasts: A multicenter, retrospective cohort study</atitle><jtitle>Cancer</jtitle><addtitle>Cancer</addtitle><date>2023-07-01</date><risdate>2023</risdate><volume>129</volume><issue>13</issue><spage>2013</spage><epage>2022</epage><pages>2013-2022</pages><issn>0008-543X</issn><eissn>1097-0142</eissn><abstract>Background
Minimal residual disease (MRD) is an important prognostic factor for survival in adults with acute leukemia. The role of pretransplantation MRD status in myelodysplastic syndrome with excess blasts (MDS‐EB) is unknown. This study retrospectively analyzed the relationship between pretransplantation MRD status and long‐term survival.
Materials and Methods
Patients with MDS‐EB who underwent allogeneic hematopoietic stem cell transplantation (allo‐HSCT) from March 5, 2005, to November 8, 2020, were included. The relationship between pretransplantation MRD status and long‐term survival was analyzed using univariate and multivariate logistic regression models.
Results
Of 220 patients with MDS‐EB who underwent allo‐HSCT, 198 were eligible for inclusion in this multicenter, retrospective cohort study. Complete remission was attained in 121 (61.1%) patients, and 103 patients underwent detection of MRD pretransplantation, with 67 patients being MRD‐positive and 36 patients being MRD‐negative. The median follow‐up time was 16 months, the median age was 41 years (6–65 years), and 58% of the patients were men. The 3‐year disease‐free survival (DFS) and overall survival (OS) probabilities for all patients were 70.1% and 72.9%, respectively. For patients in complete remission, the 3‐year DFS and OS probabilities were 72.2% and 74.8%, respectively. Further analysis found that the 3‐year DFS rates of MRD‐negative and MRD‐positive patients were 85.6% and 66.5% (p = .045), respectively, whereas the 3‐year OS rates were 91.3% and 66.4% (p = .035), respectively. Univariate and multivariate analyses showed that poor pretransplantation MRD clearance was an independent prognostic risk factor for DFS and OS.
Conclusion
Poor pretransplantation MRD clearance is an independent prognostic risk factor for long‐term survival after allo‐HSCT for patients with MDS‐EB.
Plain language summary
Poor minimal residual disease clearance pretransplanation is an independent prognostic risk factor for long‐term survival after allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome with excess blasts.
The role of minimal residual disease (MRD) status pretransplantation in the survival of patients with myelodysplastic syndrome with excess blasts after allogeneic hematopoietic stem cell transplantation in present multicenter, retrospective, cohort study was evaluated. The primary outcome showed that MRD status was the only independent prognostic factor that affects long‐term survival.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>36951498</pmid><doi>10.1002/cncr.34762</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0003-0142-3307</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0008-543X |
| ispartof | Cancer, 2023-07, Vol.129 (13), p.2013-2022 |
| issn | 0008-543X 1097-0142 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2790050835 |
| source | Wiley Free Content; MEDLINE; Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Adult Allografts Cohort analysis disease‐free survival Female Hematopoietic Stem Cell Transplantation Hematopoietic stem cells Humans independent prognostic risk Leukemia Leukemia, Myeloid, Acute Male Medical prognosis Minimal residual disease Multivariate analysis Myelodysplastic syndrome myelodysplastic syndrome with excess blasts Myelodysplastic syndromes Myelodysplastic Syndromes - therapy Neoplasm, Residual - diagnosis Oncology overall survival Prognosis Regression analysis Regression models Remission Remission (Medicine) Retrospective Studies Risk Factors Stem cell transplantation Stem cells Survival Transplantation |
| title | Poor pretransplantation minimal residual disease clearance as an independent prognostic risk factor for survival in myelodysplastic syndrome with excess blasts: A multicenter, retrospective cohort study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T11%3A44%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Poor%20pretransplantation%20minimal%20residual%20disease%20clearance%20as%20an%20independent%20prognostic%20risk%20factor%20for%20survival%20in%20myelodysplastic%20syndrome%20with%20excess%20blasts:%20A%20multicenter,%20retrospective%20cohort%20study&rft.jtitle=Cancer&rft.au=Ma,%20Ying%E2%80%90Ying&rft.date=2023-07-01&rft.volume=129&rft.issue=13&rft.spage=2013&rft.epage=2022&rft.pages=2013-2022&rft.issn=0008-543X&rft.eissn=1097-0142&rft_id=info:doi/10.1002/cncr.34762&rft_dat=%3Cproquest_cross%3E2824329892%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2824329892&rft_id=info:pmid/36951498&rfr_iscdi=true |